Biogen announced its acquisition of portfolio company Apellis Pharmaceuticals, expanding Biogen's immunology and rare disease portfolio.
Apellis Pharmaceuticals is a biotechnology company focused on developing innovative therapies for patients with serious diseases driven by the complement system
Apellis Pharmaceuticals is a biotechnology company focused on developing innovative therapies for patients with serious diseases driven by the complement system. They have pioneered the first new class of complement medicine in 15 years, targeting C3 to treat conditions such as geographic atrophy, rare kidney diseases, and paroxysmal nocturnal hemoglobinuria.